SUPERNUS PHARMACEUTICALS, INC. - 8-K Filing
Supernus Pharmaceuticals notified the Rights Agent on May 17, 2026 that it has become obligated to pay a $33.4 million milestone payment under its Contingent Value Right Agreement due to Milestone 1 being achieved on March 18, 2026. (Items: 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, 9.01 Financial Statements and Exhibits)
Tickers: $SUPN